This is a Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics, and preliminary efficacy of SCTB35 monotherapy, an bispecific antibody, in patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma.
Age ≥ 18 years
Histologically or cytologically confirmed CD20+ mature B-cell neoplasm
De novo or transformed diffuse large B-cell lymphoma (DLBCL)
High-grade B-cell lymphoma (HGBCL)
Any prior therapy with an bispecific antibody of the same class
Eligible for high dose chemotherapy with hematopoietic stem cell transplantation (HSCT)
Known central nervous system (CNS) involvement by lymphoma
Cervical carcinoma of Stage Ib or less